Series C · Biotech
Cyllene Therapeutics: Series C
Develops DNA medicines for severe neurogenic bladder conditions and other neurological diseases
Funding history
Series C · This round€33M
Loading rounds…
Develops DNA medicines for severe neurogenic bladder conditions and other neurological diseases